Malaria parasites evolve in response to antimalarial drug use and become resistant over time, resulting in periodic changes in treatment regimens. Differences in the life cycle of malaria parasites and transmission intensity among geographical regions have resulted in different antimalarial treatment regimens such as using primaquine for radical cure against P. vivax liver-stage hypnozoites and the implementation of Seasonal Malaria Chemoprevention. The issue of resistance occurs not only in antimalarial drugs but also in insecticides used for eradicating the vector, female Anopheles mosquitoes. Wide distributions of Long Lasting Insecticidal Nets (LLINs) and indoor residual spraying (IRS) are major vector control strategies to reduce the mosquito populations as well as to prevent interactions with human hosts. Nevertheless, the evolution of resistance to multiple insecticide classes in the main malaria vectors has resulted in a less effective strategy when either is employed alone. The distribution and mechanisms of insecticide resistance around the world especially in most malaria endemic regions still merit investigations to improve existing control strategies.
Drug resistance in the malaria parasite and insecticide resistance in the mosquito vector are major obstacles in the quest to eradicate malaria. As resistance in the parasite and the vector develop over time, constant surveillance is needed to help identify and track the development of resistance. Additionally, new safe and effective drugs and insecticides are needed to serve as a backup and alternative to those currently in use additionally, new drug targets are needed.
For this Research Topic, we aim to provide important insights into antimalarial drug resistance and insecticide resistance. This includes but is not limited to
1) molecular basis and/or mechanisms of antimalarial drug resistance
2) antimalarial drug and insecticide efficacy studies,
3) new and novel insecticide resistance genetic markers in mosquitoes,
4) association of mosquito midgut microbiota with insecticide resistance,
5) new methods and/or biomarkers to access antimalarial drug and/or insecticide resistance,
6) new compounds and molecules to combat antimalarial drug and/or insecticide resistance.
Original research articles, case reports, reviews and mini-reviews and method reports are welcome for this research topic.
Malaria parasites evolve in response to antimalarial drug use and become resistant over time, resulting in periodic changes in treatment regimens. Differences in the life cycle of malaria parasites and transmission intensity among geographical regions have resulted in different antimalarial treatment regimens such as using primaquine for radical cure against P. vivax liver-stage hypnozoites and the implementation of Seasonal Malaria Chemoprevention. The issue of resistance occurs not only in antimalarial drugs but also in insecticides used for eradicating the vector, female Anopheles mosquitoes. Wide distributions of Long Lasting Insecticidal Nets (LLINs) and indoor residual spraying (IRS) are major vector control strategies to reduce the mosquito populations as well as to prevent interactions with human hosts. Nevertheless, the evolution of resistance to multiple insecticide classes in the main malaria vectors has resulted in a less effective strategy when either is employed alone. The distribution and mechanisms of insecticide resistance around the world especially in most malaria endemic regions still merit investigations to improve existing control strategies.
Drug resistance in the malaria parasite and insecticide resistance in the mosquito vector are major obstacles in the quest to eradicate malaria. As resistance in the parasite and the vector develop over time, constant surveillance is needed to help identify and track the development of resistance. Additionally, new safe and effective drugs and insecticides are needed to serve as a backup and alternative to those currently in use additionally, new drug targets are needed.
For this Research Topic, we aim to provide important insights into antimalarial drug resistance and insecticide resistance. This includes but is not limited to
1) molecular basis and/or mechanisms of antimalarial drug resistance
2) antimalarial drug and insecticide efficacy studies,
3) new and novel insecticide resistance genetic markers in mosquitoes,
4) association of mosquito midgut microbiota with insecticide resistance,
5) new methods and/or biomarkers to access antimalarial drug and/or insecticide resistance,
6) new compounds and molecules to combat antimalarial drug and/or insecticide resistance.
Original research articles, case reports, reviews and mini-reviews and method reports are welcome for this research topic.
